Alvogen — company profile
Alvogen Pharma US, Inc. ("Alvogen"), whose ultimate parent is New Alvogen Group Holdings, Inc., is a privately held pharmaceutical company founded in 2009 by Icelandic entrepreneur Róbert Wessman. It is headquartered in New Jersey (sources cite both Morristown and Pine Brook). Since 2015 it was majority-owned by CVC Capital Partners and Temasek Holdings, with Athyrium Capital Management also an investor. In September 2025 its shareholders agreed to sell the parent to Lotus Pharmaceutical Co., Ltd. (TWSE: 1795); Alvogen is now described as a controlled subsidiary of Lotus. Reported size varies by source — the company's own materials cite roughly 2,800 employees and commercial operations in about 35 countries, with four manufacturing/development hubs (US, Romania, South Korea, Taiwan); third-party estimates range from ~2,400 to ~2,900 employees and from roughly $180M to $1B in revenue, so revenue figures should be treated as unverified.
Alvogen develops, in-licenses, manufactures and markets generic, branded, over-the-counter and biosimilar pharmaceuticals. Its stated focus is complex, higher-value products including inhalation, long-acting injectables, peptides and 505(b)(2) brand products, with therapeutic coverage in oncology, cardiology, respiratory, neurology and gastroenterology. It reports 30-plus marketed products, a pipeline of roughly 200 development/registration projects, and in-house US manufacturing at Norwich, New York.
Patent-litigation posture: operating company, not an NPE. The tracked data show 0 plaintiff cases and 1 defendant case — consistent with a generic manufacturer defending brand-company infringement suits. That single case was filed in the U.S. District Court for the District of New Jersey, Alvogen's home forum, not a plaintiff-friendly venue such as the Eastern District of Texas.
Notable case: Celgene Corporation v. Synthon Pharmaceuticals, Inc. et al. (D.N.J., filed April 12, 2019), in which Alvogen Pine Brook, LLC was named a defendant alongside Synthon Pharmaceuticals Inc., Synthon B.V. and Synthon s.r.o. It was a Hatch-Waxman ANDA action over pomalidomide (Pomalyst) capsules under ANDA No. 210232. The parties resolved the matter by consent judgment in May 2019, dismissing the case with prejudice and entering an injunction. Note that this database captures only one Alvogen appearance; the company has been involved in other ANDA litigation not reflected here.